Regulatory Hurdles and Potential Consequences

Irish biotechnology firm Trinity Biotech is navigating a period of significant challenge and opportunity as it approaches a decisive Nasdaq compliance deadline on September 10, 2025. The company must successfully meet two critical listing requirements to avoid immediate delisting from the Nasdaq Global Select Market.

For continued listing, Trinity Biotech’s share price must close at or above $1.00 for a minimum of ten consecutive trading days. Simultaneously, the market value of its publicly Read more...